News

Veeva OpenData and Veeva Network Enable Coordinated Customer Engagement for Boehringer Ingelheim
Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data ...
Fierce Biotech1d
'Crossing fingers': Boehringer awaits key FDA decisions to spearhead 'maturing' pipeline
It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer ...
MedPage Today on MSN13h
What Happened to Our Brains During the Pandemic?
"Longer follow-ups after the pandemic are needed to investigate persistent brain aging effects and their long-term ...
Animal spirits: Zenex investors dial bankers for $1 billion sale or IPO
After Advent's Felix Pharma buyout, another deal is brewing in the vet medicine segment. Multiples and other investors of ...
Informationsdienst Wissenschaft2d
New funding for EMBL’s cutting-edge imaging technology services
Mainz, 22 July 2025. Boehringer Ingelheim Stiftung commits 7 million euros to support the EMBL Imaging Centre in Heidelberg. Boehringer Ingelheim Stiftung, Dr Friederike Keggenhoff, Officer, Web: ...
Healio17h
FDA approves Anzupgo for chronic hand eczema
The FDA approved Anzupgo for the treatment of moderate to severe chronic hand eczema in adults who do not adequately respond ...
TCTMD14h
Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data
The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.
With Damaging Delaware Decision and No Plaintiff Verdicts, What’s the Future for Zantac Lawsuits?
This month in the Zantac litigation, the Delaware Supreme Court tossed all the plaintiffs’ experts in thousands of cases, ...
PMLive3d
LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront
LEO Pharma and Boehringer Ingelheim have entered into a partnership to commercialise and advance the development of ...